ArticleJournal of molecular histology2026
Bioinformatics screening identifies USP9X as a pathogenic gene underlying thyroid and breast cancer comorbidity.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The co-occurrence of thyroid cancer (TC) and breast cancer (BC) has attracted much attention in recent years. The aim of the study was to explore the potential molecular mechanisms in the comorbidity of TC and BC. We identified the differentially expressed genes (DEGs) for TC and BC using the TCGA database and screened the common driver genes for the comorbidity of TC and BC. Immunohistochemical staining was performed to verify the expression of the common gene (USP9X) in double primary cancers (co-occurrence of TC and BC). Migration, invasion and colony formation assays were used to evaluate the role of USP9X in TC and BC cells in vitro. In the present study, we confirmed 8 driver genes shared by TC and BC through bioinformatics analysis. In samples with co-occurring TC and BC, USP9X immunoreactivity was detected in 100% (14/14) TC and 100% (14/14) BC samples. Interfering with USP9X expression could inhibit the colony formation, migration and invasion abilities of TC and BC cells. Protein-protein interaction network analysis revealed USP9X/MCL-1 and USP9X/NUAK1 might be molecular pathways involved in the comorbidity of TC and BC. Our findings suggest that USP9X overexpression is a molecular event involved in the comorbidity of TC and BC and it could be a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.